Myricx Bio

Myricx Bio is a UK-based biotechnology company specializing in the discovery and development of a new class of selective cytotoxic payloads for antibody-drug conjugates (ADCs). These ADCs are based on inhibitors of the enzyme NMT (N-myristoyltransferase) and are designed to treat various types of cancer. The company operates in the biopharmaceutical market, targeting oncology therapeutics. Myricx Bio serves pharmaceutical companies and research institutions looking for advanced cancer treatment solutions. The business model revolves around research and development, followed by licensing agreements and partnerships with larger pharmaceutical firms to bring their innovations to market. Revenue is generated through these partnerships, licensing deals, and potentially future sales of developed therapies.

Keywords: biotechnology, ADCs, NMT inhibitors, cancer treatment, oncology, cytotoxic payloads, drug development, licensing, partnerships, UK-based.